These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 24127257

  • 21. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC, Durocher F, Smith P, Simard J, Easton DF, INHERIT BRCAs program members.
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [Abstract] [Full Text] [Related]

  • 22. Spontaneous disclosure of BRCA1/2 genetic test results to employers: a French prospective study.
    Eisinger F, Fabre R, Lasset C, Stoppa-Lyonnet D, Julian-Reynier C, Nogues C.
    Eur J Hum Genet; 2012 Sep; 20(9):981-3. PubMed ID: 22378286
    [Abstract] [Full Text] [Related]

  • 23. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
    Dorval M, Gauthier G, Maunsell E, Dugas MJ, Rouleau I, Chiquette J, Plante M, Laframboise R, Gaudet M, Bridge PJ, Simard J.
    Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2862-7. PubMed ID: 16365001
    [Abstract] [Full Text] [Related]

  • 24. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study.
    van Oostrom I, Meijers-Heijboer H, Lodder LN, Duivenvoorden HJ, van Gool AR, Seynaeve C, van der Meer CA, Klijn JG, van Geel BN, Burger CW, Wladimiroff JW, Tibben A.
    J Clin Oncol; 2003 Oct 15; 21(20):3867-74. PubMed ID: 14551306
    [Abstract] [Full Text] [Related]

  • 25. What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?
    Bosch N, Junyent N, Gadea N, Brunet J, Ramon y Cajal T, Torres A, Graña B, Velasco A, Darder E, Mensa I, Balmaña J.
    Breast; 2012 Dec 15; 21(6):755-60. PubMed ID: 22381151
    [Abstract] [Full Text] [Related]

  • 26. Psychological impact of receiving a BRCA1/BRCA2 test result.
    Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, van der Meer CA, van den Ouweland AM, Niermeijer MF.
    Am J Med Genet; 2001 Jan 01; 98(1):15-24. PubMed ID: 11426450
    [Abstract] [Full Text] [Related]

  • 27. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.
    J Clin Oncol; 2003 May 01; 21(9):1675-81. PubMed ID: 12721241
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.
    Friebel TM, Domchek SM, Neuhausen SL, Wagner T, Evans DG, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson G, Lynch HT, Tung N, Blum JL, Weitzel J, Rubinstein WS, Ganz PA, Couch F, Rebbeck TR.
    Clin Breast Cancer; 2007 Dec 01; 7(11):875-82. PubMed ID: 18269778
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems.
    Hallowell N, Ardern-Jones A, Eeles R, Foster C, Lucassen A, Moynihan C, Watson M.
    Clin Genet; 2005 Jun 01; 67(6):492-502. PubMed ID: 15857416
    [Abstract] [Full Text] [Related]

  • 36. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
    Kauff ND, Mitra N, Robson ME, Hurley KE, Chuai S, Goldfrank D, Wadsworth E, Lee J, Cigler T, Borgen PI, Norton L, Barakat RR, Offit K.
    J Natl Cancer Inst; 2005 Sep 21; 97(18):1382-4. PubMed ID: 16174860
    [Abstract] [Full Text] [Related]

  • 37. Benefit finding in response to BRCA1/2 testing.
    Low CA, Bower JE, Kwan L, Seldon J.
    Ann Behav Med; 2008 Feb 21; 35(1):61-9. PubMed ID: 18347905
    [Abstract] [Full Text] [Related]

  • 38. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 21; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.
    Lerman C, Hughes C, Croyle RT, Main D, Durham C, Snyder C, Bonney A, Lynch JF, Narod SA, Lynch HT.
    Prev Med; 2000 Jul 21; 31(1):75-80. PubMed ID: 10896846
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.